Free accessReview articleFirst published online 2008-10
Review: Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma
Although the available inhaled corticosteroid (ICS)/long-acting β 2-agonist (LABA) combinations principally work in a similar fashion, they differ in several important ways, leading to different efficacy. The ICS/LABA combination product budesonide/formoterol can be used as both maintenance and reliever therapy, providing a fixed maintenance dose, which does not change, and replacing short-acting β2-agonists as relievers thereby allowing intervention to address the underlying inflammation at the earliest sign of symptomatic worsening. This approach is not suitable for other combination products such as salmeterol/fluticasone. Here we review the pharmacological differences of budesonide/ formoterol and salmeterol/fluticasone that permit the use of budesonide/formoterol as both maintenance and reliever therapy.
Aalbers, R., Backer, V., Kava, T.T., Omenaas, E.R., Sandstrom, T., Jorup, C. et al. (2004) Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma . Curr Med Res Opin20(2): 225-240.
2.
Adachi, M., Ohta, K., Morikawa, A., Nishima, S., Tokunaga, S. and Disantostefano, R.L. (2008) Changes in asthma insights and reality in Japan (AIRJ) in 2005 since 2000. Arerugi57(2): 107-120 [in Japanese].
3.
Anderson, G.P. (1993) Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci52(26): 2145-2160.
4.
Anderson, G.P. (2000) Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation. Am J Respir Crit Care Med161(3 Pt 2): S188-S196.
5.
Bai, T.R., Vonk, J.M., Postma, D.S. and Boezen, H.M. (2007) Severe exacerbations predict excess lung function decline in asthma. Eur Respir J30(3): 452-456.
6.
Barnes, P.J. (2007) Scientific rationale for using a single inhaler for asthma control. Eur Respir J29(3): 587-595.
7.
Bateman, E.D., Boushey, H.A., Bousquet, J., Busse, W.W., Clark, T.J., Pauwels, R.J. et al. (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med170(8): 836-844.
8.
Bennett, J.A. and Tattersfield, A.E. (1997) Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax52(5): 458-464.
9.
Bisgaard, H., Le Roux, P., Bjåmer, D., Dymek, A., Vermeulen, J.H. and Hultquist, C. (2006) Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest130(6): 1733-1743.
10.
Boonsawat, W., Charoenratanakul, S., Pothirat, C., Sawanyawisuth, K., Seearamroongruang, T., Bengtsson, T. et al. (2003) Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med97(9): 1067-1074.
11.
Bousquet, J., Boulet, L.P., Peters, M.J., Magnussen, H., Quiralte, J., Martinez-Aguilar, N.E. et al. (2007) Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med101(12): 2437-2446.
12.
Busse, W., Chervinsky, P., Condemi, J., Lumry, W.R., Petty, T.L., Rennard, S. et al. (1998) Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol101(4 Pt 1): 457-463.
13.
Cazzola, M. and Curradi, G. (2007) How to prevent relapse after acute exacerbation of asthma? Pol Arch Med Wewn117(11-12): 487-490.
14.
Cazzoletti, L., Marcon, A., Janson, C., Corsico, A., Jarvis, D., Pin, I. et al. (2007) Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol120(6): 1360-1367.
15.
Chapman, K.R., Boulet, L.P., Rea, R.M. and Franssen, E. (2008) Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J31(2): 320-325.
16.
Cheung, D., van Klink, H.C. and Aalbers, R.(2006) Improved lung function and symptom control with formoterol on demand in asthma. Eur Respir J27(3): 504-510.
17.
Currie, G.P., Jackson, C.M., Ogston, S.A. and Lipworth, B.J. (2003) Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids. QJM96(6): 435-440.
18.
Dahl, R., Chuchalin, A., Gor, D., Yoxall, S. and Sharma, R. (2006) EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med100(7): 1152-1162.
19.
Desfougeres, J.-L., Sohier, B. and Freedman, D. (2007) Has asthma control improved since AIRE? Results of a survey in 5 European countries. Eur Respir J30(Suppl.): 249s.
20.
D'Urzo, A.D., Chapman, K.R., Cartier, A., Hargreave, F.E., Fitzgerald, M. and Tesarowski, D. (2001) Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest119(5): 714-719.
21.
Edsbäcker, S., Wollmer, P., Selroos, O., Borgström, L., Olsson, B. and Ingelf, J. (2008) Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther21(2): 247-258.
22.
Edwards, S.J., Gruffydd-Jones, K. and Ryan, D. (2007) Systematic review and meta-analysis of budesonide/formoterol in a single inhaler. Curr Med Res Opin23(8): 1809-1820.
23.
Faulds, D., Hollingshead, L.M. and Goa, K.L. (1991) Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs42(1): 115-137.
24.
Fitzgerald, J.M., Becker, A., Sear, M.R., Mink, S., Chung, K. and Lee, J. (2004) Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax59(7): 550-556.
25.
Foresi, A., Morelli, M.C. and Catena, E. (2000) Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest117(2): 440-446.
26.
Global Initiative for Asthma (GINA) (2007) Global strategy for asthma management and prevention - updated 2007 . Available at: www.ginasthma.com, accessed January 2008.
27.
Guhan, A.R., Cooper, S., Osbourne, J., Lewis, S., Bennett, J. and Tattersfield, A.E. (2000) Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax55(8): 650-656.
28.
Greening, A.P., Ind, P.W., Northfield, M. and Shaw, G. (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet344(8917): 219-224.
29.
Harrison, T.W., Oborne, J., Newton, S. and Tattersfield, A.E. (2004) Doubling the dose of inhaled corticosteroid to prevent exacerbations: randomised controlled trial. Lancet363(9405): 271-275.
30.
Harrison, T.W. and Tattersfield, A.E. (2003) Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax58(3): 258-260.
31.
Heyneman, C.A., Crafts, R., Holland, J. and Arnold, A.D. (2002) Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control. Ann Pharmacother36(12): 1944-1949.
32.
Jaeschke, R., Mejza, F., Lesniak, W., Brozek, J., Schunemann, H.J., Guyatt, G. et al. (2007) The safety of formoterol among patients with asthma using inhaled corticosteroids. Am J Respir Crit Care Med175: A57.
33.
Juniper, E.F., Kline, P.A., Vanzielegham, M.A., Ramsdale, E.H., O'Byrne, P.M. and Hargreave, F.E. (1990) Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in non-steroid dependent asthmatics. Am Rev Respir Dis142(4): 832-836.
34.
Kuna, P., Peters, M.J., Manjra, A.I., Jorup, C., Naya, I.P., Martinez-Jimenez, N.E. et al. (2007) Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract61(5): 725-736.
35.
Laitinen, L.A., Laitinen, A. and Haahtela, T. (1992) A comparative study on the effects of an inhaled corticosteroid, budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol90(1): 32-42.
36.
Levy, M.L. (2008) Guideline-defined asthma control: a challenge for primary care. Eur Respir J31(2): 229-231.
37.
Lötvall, J. (2001) Pharmacological similarities and differences between beta2-agonists. Respir Med95(Suppl B): S7-S11.
38.
Lötvall, J., Langley, S. and Woodcock, A. (2006) Inhaled steroid/long-acting beta-2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients. Respir Res7(Aug 18): 110.
39.
Masoli, M., Fabian, D., Holt, S. and Beasley, R. (2004) The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy59(5): 469-478.
40.
Miller-Larsson, A., Mattsson, H., Hjertberg, E., Dahlbäck, M., Tunek, A. and Brattsand, R. (1998) Reversible fatty acid conjugation of budesonide: novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos26(7): 623-630.
41.
Miyamoto, T., Takahashi, T., Nakajima, S., Makino, S., Yamakido, M., Mano, K. et al. (2000) A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Respirology5(3): 247-256.
42.
Naya, I.P. and Andersson, T.L. (2007) Post hoc analysis and claims of superiority in the EXCEL trial. Respir Med101(3): 681-682.
43.
Nelson, H.S., Beasley, R., Yancey, S.W., Kral, K.M., Edwards, L.D., Sutton, L.B. et al. (2007) No increase in asthma-related hospitalizations following the addition of salmeterol to an inhaled corticosteroid in patients with asthma: a meta-analysis. Am J Respir Crit Care Med175: A59.
44.
NICE Technology Appraisal Guidance 138 (2008 ) Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over. Available at: www.nice.org.uk/TA138
45.
O'Byrne, P.M., Barnes, P.J., Rodriguez-Roisin, R., Runnerstrom, E., Sandstrom, T., Svensson, K. et al. (2001) Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med164(8 Pt 1): 1392-1397.
46.
O'Byrne, P.M., Bisgaard, H., Godard, P.P., Pistolesi, M., Palmqvist, M., Zhu, Y. et al. (2005) Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med171(2): 129-136.
47.
Palmqvist, M., Arvidsson, P., Beckman, O., Peterson, S. and Lotvall, J. (2001) Onset of bronchodilation of budesonide/formoterol versus salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther14(1): 29-34.
48.
Palmqvist, M., Ibsen, T., Mellen, A. and Lotvall, J. (1999) Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med160(1): 244-249.
49.
Papi, A., Paggiaro, P.L., Nicolini, G., Vignola, A.M. and Fabbri, L. (2007) Beclomethasone/formoterol vs budesonide/formoterol combination therapy in asthma. Eur Respir J29(4): 682-689. Erratum in: Eur Respir J (2007) 29(6): 1286.
50.
Partridge, M.R., Van der Molen, M.T., Myrseth, S.E. and Busse, W.W. (2006) Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med6(June 13): 13.
51.
Pauwels, R.A., Löfdahl, C.G., Postma, D.S., Tattersfield, A.E., O'Byrne, P.M., Barnes, P.J., et al. (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med337(20): 1405-1411. Erratum in: N Engl J Med (1998) 338(2): 139.
52.
Pauwels, R.A., Sears, M.R., Campbell, M., Villasante, C., Huang, S., Lindh, A. et al. (2003) Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J22(5): 787-794.
53.
Pohunek, P., Matulka, M., Rybnicek, O., Kopriva, F., Honomichlova, H. and Svobodova, T. (2004) Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma . Pediatr Allergy Immunol15(1): 32-39.
54.
Rabe, K.F., Adachi, M., Lai, C.K., Soriano, J.B., Vermeire, P.A., Weiss, K.B. et al. (2004) Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol114(1): 40-47.
55.
Rabe, K.F., Atienza, T., Magyar, P., Larsson, P., Jorup, C. and Lalloo, U.G. (2006b) Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet368(9537): 744-753.
56.
Rabe, K.F., Pizzichini, E., Stallberg, B., Romero, S., Balanzat, A.M., Atienza, T. et al. (2006a) Budesonide/ formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest129(2): 246-256.
57.
Rabe, K.F., Vermeire, P.A., Soriano, J.B. and Maier, W.C. (2000) Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J16(5): 802-807.
58.
Scicchitano, R., Aalbers, R., Ukena, D., Manjra, A., Fouquert, L., Centanni, S. et al. (2004) Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin20(9): 1403-1418.
59.
Seberová, E. and Andersson, A. (2000) Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med94(6): 607-611.
60.
Shrewsbury, S., Pyke, S. and Britton, M. (2000) Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ320(7246): 1368-1373.
61.
Tattersfield, A.E., Postma, D.S., Barnes, P.J., Svensson, K., Bauer, C.A., O'Byrne, P.M. et al. (1999) Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med160(2): 594-599.
62.
Tattersfield, A.E., Lofdahl, C.G., Postma, D.S., Eivindson, A., Schreurs, A.G., Rasidakis, A. et al. (2001) Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet357(9252): 257-261.
63.
Thorsson, L., Edsbäcker, S., Källén, A. and Lofdahl, C.-G. (2001) Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol52(5): 529-538.
64.
Toogood, J.H., Baskerville, J.C., Jennings, B., Lefcoe, N.M. and Johansson, S.A. (1982) Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid budesonide. J Allergy Clin Immunol70(4): 288-298.
65.
Tunek, A., Sjödin, K. and Hallström, G. (1997) Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos11(11): 1311-1317.
66.
van den Nieuwenhof, L., Schermer, T., Heins, M., Bottema, B., van Weel, C., Bindels, P. et al. (2008) Tracing uncontrolled asthma in family practice using a mailed asthma control questionnaire. Ann Fam Med6(Suppl. 1): S16-S22.
67.
van der Woude, H.J., Boorsma, M., Bergqvist, P.B., Winter, T.H. and Aalbers, R. (2004) Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther17(2): 89-95.
68.
Vogelmeier, C., D'Urzo, A., Pauwels, R., Merino, J.M., Jaspal, M., Boutet, S. et al. (2005) Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?Eur Respir J26(5): 819-828.
69.
Wieslander, E., Delander, E.-L., Sjödin, K. and Miller-Larsson, A. (1998) Fatty acid conjugation in normal human bronchial epithelial cells. Am J Respir Crit Care Med157: A402.
70.
Woolcock, A., Lundback, B., Ringdal, N. and Jacques, L.A. (1996) Comparison of addition of V salmeterol to inhaled steroids with doubling of the h dose of inhaled steroids. Am J Respir Crit Care Med153(5): 1481-1488.
